keyword
MENU ▼
Read by QxMD icon Read
search

"Non-small cell lung cancer" AND gemcitabine

keyword
https://www.readbyqxmd.com/read/28693283/prospective-exploratory-study-of-gemcitabine-and-s-1-against-elderly-patients-with-advanced-non-small-cell-lung-cancer
#1
Kyoichi Kaira, Noriko Yanagitani, Noriaki Sunaga, Hisao Imai, Akihiro Ono, Yasuhiko Koga, Takeshi Hisada, Tamotsu Ishizuka, Masanobu Yamada
A prospective study was conducted to investigate the efficacy of a combined regimen of gemcitabine and S-1 for the treatment of elderly patients (>70 years) with advanced non-small cell lung cancer (NSCLC) as a first-line setting based on the dosage recommended in a previous phase I study. Chemotherapy-naïve patients with advanced NSCLC received gemcitabine plus S-1. S-1 (40 mg/m(2)) was administered orally twice daily for 14 days while gemcitabine (1,000 mg/m(2)) was administered on days 1 and 15 of each cycle, and this regimen was repeated every 4 weeks...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28668866/histology-based-combination-induction-chemotherapy-for-elderly-patients-with-clinical-stage-iii-non-small-cell-lung-cancer
#2
Giuseppe L Banna, Hector Josè Soto Parra, Marine Castaing, Maria Vittoria Dieci, Giuseppe Anile, Maurizio Nicolosi, Salvatore Strano, Francesco Marletta, Valentina Guarneri, Pierfranco Conte, Rohit Lal
AIM: To explore the feasibility and activity of a histology-based induction combination chemotherapy for elderly patients with clinical stage III non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients aged ≥70 years with stage IIIA and IIIB lung squamous cell carcinoma (SCC) or adenocarcinoma were treated with three cycles of carboplatin and gemcitabine or pemetrexed, respectively, followed by definitive radiotherapy or surgery. The primary endpoint was the overall response rate (ORR) following induction...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28577946/reduced-smad4-expression-and-dna-topoisomerase-inhibitor-chemosensitivity-in-non-small-cell-lung-cancer
#3
Michael Ziemke, Tejas Patil, Kyle Nolan, Darinee Tippimanchai, Stephen P Malkoski
OBJECTIVE: Smad4 is a tumor suppressor that transduces transforming growth factor beta signaling and regulates genomic stability. We previously found that Smad4 knockdown in vitro inhibited DNA repair and increased sensitivity to DNA topoisomerase inhibitors. In this study, we assessed the association between reduced Smad4 expression and DNA topoisomerase inhibitor sensitivity in human non-small cell lung cancer (NSCLC) patients and evaluated the relationship between genomic alterations of Smad4 and molecular alterations in DNA repair molecules...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28569042/exposure-response-analysis-of-necitumumab-efficacy-in-squamous-non-small-cell-lung-cancer-patients
#4
Emmanuel Chigutsa, Amanda J Long, Johan E Wallin
We sought to describe the exposure-response relationship of necitumumab efficacy in squamous non-small cell lung cancer patients and evaluate intrinsic and extrinsic patient descriptors that may guide dosing. SQUIRE was a phase 3 study comparing necitumumab in combination with gemcitabine and cisplatin versus gemcitabine and cisplatin alone in 1014 patients. An integrated model for tumor size dynamics and overall survival was developed, where reduction in tumor size results in a decrease in survival hazard...
May 31, 2017: CPT: Pharmacometrics & Systems Pharmacology
https://www.readbyqxmd.com/read/28504964/meta-analysis-comparing-the-efficacy-of-nedaplatin-based-regimens-between-squamous-cell-and-non-squamous-cell-lung-cancers
#5
Yijun Tian, Qian Liu, Kongju Wu, Qian Chu, Yuan Chen, Kongming Wu
Non-small cell lung cancer (NSCLC) consists of several subtypes, including adenocarcinoma, squamous cell lung cancer, large cell lung cancer, and other rarer types. Platinum-based regimens are currently the standard for treatment of advanced NSCLC. Nedaplatin is reportedly associated with a high response rate in squamous cell lung cancer. However, the relevant studies are small and mainly descriptive. The purpose of this meta-analysis was therefore to compare the efficacy of nedaplatin in squamous cell lung cancer with that in non-squamous cell lung cancer...
April 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28500236/identification-of-the-serine-biosynthesis-pathway-as-a-critical-component-of-braf-inhibitor-resistance-of-melanoma-pancreatic-and-non-small-cell-lung-cancer-cells
#6
Kayleigh C Ross, Andrew J Andrews, Christopher D Marion, Timothy J Yen, Vikram Bhattacharjee
Metastatic melanoma cells commonly acquire resistance to BRAF V600E inhibitors (BRAFis). In this study, we identified serine biosynthesis as a critical mechanism of resistance. Proteomic assays revealed differential protein expression of serine biosynthetic enzymes PHGDH, PSPH, and PSAT1 following vemurafenib (BRAFi) treatment in sensitive versus acquired resistant melanoma cells. Ablation of PHGDH via siRNA sensitized acquired resistant cells to vemurafenib. Inhibiting the folate cycle, directly downstream of serine synthesis, with methotrexate also displayed similar sensitization...
May 12, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28489511/phase-iii-randomized-placebo-controlled-double-blind-trial-of-celecoxib-in-addition-to-standard-chemotherapy-for-advanced-non-small-cell-lung-cancer-with-cyclooxygenase-2-overexpression-calgb-30801-alliance
#7
Martin J Edelman, Xiaofei Wang, Lydia Hodgson, Richard T Cheney, Maria Q Baggstrom, Sachdev P Thomas, Ajeet Gajra, Erin Bertino, Karen L Reckamp, Julian Molina, Joan H Schiller, Kisha Mitchell-Richards, Paula N Friedman, Jon Ritter, Ginger Milne, Olwen M Hahn, Thomas E Stinchcombe, Everett E Vokes
Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with worse outcome in non-small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B (CALGB) 30203, we found that the selective COX-2 inhibitor celecoxib in addition to chemotherapy in advanced NSCLC improved progression-free and overall survival in patients with moderate to high COX-2 expression by immunohistochemistry (IHC). CALGB 30801 (Alliance) was designed to prospectively confirm that finding. Patients and Methods Patients with NSCLC (stage IIIB with pleural effusion or stage IV according to American Joint Committee on Cancer [sixth edition] criteria) were preregistered, and biopsy specimens were analyzed for COX-2 by IHC...
July 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28472787/prognostic-index-for-survival-in-patients-with-advanced-non-small-cell-lung-cancer-treated-with-third-generation-agents
#8
Mari Kogo, Tomiko Sunaga, Shoko Nakamura, Takahiro Akita, Tatsuya Kurihara, Yusuke Shikama, Hiroaki Nakajima, Takashi Tobe, Keiichiro Yoneyama, Yuji Kiuchi
We retrospectively evaluated clinical data from patients with advanced non-small-cell lung cancer (NSCLC) treated with third-generation chemotherapy agents prior to treatment, to determine a reliable method for predicting prognosis in such patients. We analyzed 100 patients who received third-generation agents (paclitaxel, docetaxel, gemcitabine, irinotecan, and vinorelbine) for the treatment of advanced NSCLC. Factors significantly related to prognosis were evaluated using the Cox regression model, and the prognostic index (PI) was determined by combining these factors...
2017: Chemotherapy
https://www.readbyqxmd.com/read/28469143/impact-of-platinum-pemetrexed-combination-versus-other-platinum-based-regimens-on-adjuvant-chemotherapy-in-resected-lung-adenocarcinoma
#9
Xiaoyu Zhai, Qiwen Zheng, Lu Yang, Yixiang Zhu, Junling Li, Yutao Liu, Ziping Wang
For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known to result in a longer survival compared with other regimens, the outcome in the adjuvant setting is still unknown. In this study, the difference of the disease-free survival (DFS) between lung adenocarcinoma patients treated with platinum/pemetrexed and with other platinum-based doublets was concerned. A total of 389 radically resected lung adenocarcinoma patients received adjuvant chemotherapy with platinum/pemetrexed chemotherapy (Group A, n = 143) or other third generation platinum-based regimens (Group B, n = 246) were analyzed in terms of DFS...
May 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28412028/-effectiveness-of-erlotinib-in-critical-care-unit-in-patients-with-non-small-cell-lung-cancer-with-egfr-mutation
#10
M Dewolf, C Dayen, C Garoute, W Khamis, M Fourrier, F Rousselle, M Sadki, F Le Meunier, R Suguenot, E Lecuyer, H Bentayeb, Y Douadi, P Berna
INTRODUCTION: The search for mutations epidermal growth factor receptor (EGFR) has changed the therapeutic approach and prognosis of non-small cell lung cancer (NSCLC). The effectiveness of tyrosine kinase inhibitors (TKI) has been demonstrated orally in patients with EGFR mutation. We report the case of a patient for whom treatment with TKI was started effectively in a Critical Care Unit. OBSERVATION: A patient of 59 years is followed for a stage IV lung adenocarcinoma with metastases in liver, brain, adrenal, lung and pleura...
June 2017: Revue de Pneumologie Clinique
https://www.readbyqxmd.com/read/28407465/kras-g12c-mutation-as-a-poor-prognostic-marker-of-pemetrexed-treatment-in-non-small-cell-lung-cancer
#11
Sehhoon Park, Ji-Yeon Kim, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
BACKGROUND/AIMS: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based treatment. METHODS: Advanced NSCLC patients tested for KRAS mutation (n = 334) were retrospectively reviewed and 252 patients with wild type epidermal growth factor receptor and no anaplastic lymphoma kinase fusion were enrolled for the analysis...
May 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28365238/an-open-label-randomized-controlled-phase-ii-study-of-paclitaxel-carboplatin-chemotherapy-with-necitumumab-versus-paclitaxel-carboplatin-alone-in-first-line-treatment-of-patients-with-stage-iv-squamous-non-small-cell-lung-cancer
#12
David R Spigel, Alexander Luft, Henrik Depenbrock, Rodryg Ramlau, Mazen Khalil, Joo-Hang Kim, Carlos Mayo, Grace Yi Chao, Coleman Obasaju, Ronald Natale
BACKGROUND: The combination of necitumumab with gemcitabine-cisplatin significantly improved overall survival (OS) in patients with stage IV squamous non-small-cell lung cancer (NSCLC), in the phase III SQUamous NSCLC treatment with the Inhibitor of EGF REceptor (SQUIRE) trial. Paclitaxel-carboplatin was selected as an alternative standard of care in the current phase II study. PATIENTS AND METHODS: Patients were randomized (stratified according to Eastern Cooperative Oncology Group performance status and sex) 2:1 to ≤ six 3-week cycles (Q3W) of paclitaxel and carboplatin with or without necitumumab...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28351036/hypoxia-induces-multidrug-resistance-via-enhancement-of-epidermal-growth-factor-like-domain-7-expression-in-non-small-lung-cancer-cells
#13
Xiaochun Shen, Qiaoming Zhi, Yunliang Wang, Zhi Li, Jin Zhou, Jianan Huang
Chemotherapy is widely used in non-small cell lung cancer (NSCLC) treatment, yet multidrug resistance (MDR) is a major chemotherapeutic obstacle in both resectable and advanced NSCLC. Epidermal growth factor-like domain 7 (EGFL7), also known as vascular endothelial stain, is an endothelial cell-derived secreted factor that regulates vascular tube formulation. The aim of this study was to investigate the potential relationships between EGFL7 and MDR in NSCLC cells. We first obtained the CDDP-based MDR phenotype cell line A549/CDDP by repeated exposure to a proper concentration of CDDP (cisplatin) from original A549 cells...
2017: Chemotherapy
https://www.readbyqxmd.com/read/28344046/long-term-outcomes-of-induction-carboplatin-and-gemcitabine-followed-by-concurrent-radiotherapy-with-low-dose-paclitaxel-and-gemcitabine-for-stage-iii-non-small-cell-lung%C3%A2-cancer
#14
Catherine Guilbault, Aurelie Garant, Sergio Faria, Scott Owen, Linda Ofiara, Marie Duclos, Vera Hirsh, Neil Kopek
BACKGROUND: Standard treatment for unresectable stage III non-small-cell lung cancer (NSCLC) is concurrent chemo-radiation (CRT). A regimen of induction carboplatin and gemcitabine followed by CRT was developed at the McGill University Health Centre to prevent delays in treatment initiation. We report the long-term outcomes with this regimen based on a pooled analysis of both protocol patients from a phase II study and nonprotocol patients. METHODS AND MATERIALS: Outcomes and toxicity data were retrieved for 142 patients with stage III NSCLC: 43 patients treated on protocol between January 2003 and November 2004, and 101 patients treated off-protocol between December 2004 and August 2013...
March 1, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28341958/randomized-phase-ii-study-comparing-weekly-docetaxel-cisplatin-vs-gemcitabine-cisplatin-in-elderly-or-poor-performance-status-patients-with-advanced-non-small-cell-lung-cancer
#15
RANDOMIZED CONTROLLED TRIAL
JoungSoon Jang, Hoon-Kyo Kim, Byoung Chul Cho, Kyung Hee Lee, Hwan-Jung Yun, In Sook Woo, Hong Suk Song, Hun-Mo Ryoo, Chi-Hong Kim, Der-Sheng Sun, Jong Wook Shin
BACKGROUND: Docetaxel/cisplatin (DP) and gemcitabine/cisplatin (GP) are standard treatment regimens for advanced non-small cell lung cancer (NSCLC). In spite of potent efficacy, the conventional 1-day DP is regarded as having more toxicity as compared with GP. There is increasing interest in a biweekly split administration of DP to reduce its toxicity. Hypothesis was that first-line biweekly DP is as safe as GP in the elderly or poor performance status (PS) patients. METHODS: Chemotherapy-naïve patients with advanced NSCLC (IIIB/IV) who were elderly (65<) or PS (ECOG 2) were randomized to DP or GP arm by balancing for ECOG (0-1 vs...
May 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28293555/second-line-treatment-of-non-small-cell-lung-cancer-clinical-pathological-and-molecular-aspects-of-nintedanib
#16
REVIEW
Luis Corrales, Amanda Nogueira, Francesco Passiglia, Angela Listi, Christian Caglevic, Marco Giallombardo, Luis Raez, Edgardo Santos, Christian Rolfo
Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targetable oncogenic drivers are docetaxel, gemcitabine, pemetrexed, and erlotinib and for patients with target-specific oncogenes afatinib, osimertinib, crizotinib, alectinib, and ceritinib. In recent years, evidence on the role of antiangiogenic agents have been established as important and effective therapeutic targets in non-small cell lung cancer (NSCLC)...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28285686/pilot-phase-ii-study-of-metronomic-chemotherapy-in-combination-with-bevacizumab-in-patients-with-advanced-non-squamous-non-small-cell-lung-cancer
#17
Benjamin S Jones, Mary S Jerome, Deborah Miley, Bradford E Jackson, Mollie R DeShazo, Vishnu V B Reddy, Karan P Singh, Olivia C Brown, Francisco Robert
INTRODUCTION: The goal of this study was to explore the efficacy and tolerability of metronomic chemotherapy, a novel anti-angiogenic treatment strategy, in combination with bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). METHODS: Subjects with newly diagnosed stage IV NSCLC were treated with 4-week cycles of paclitaxel 80mg/m(2) and gemcitabine 300mg/m(2) weekly for three weeks, plus bevacizumab 10mg/kg every two weeks. Radiologic assessments were performed every 8 weeks...
April 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28280336/tumor-targeted-polymeric-nanostructured-lipid-carriers-with-precise-ratiometric-control-over-dual-drug-loading-for-combination-therapy-in-non-small-cell-lung-cancer
#18
Yan Liang, Baocheng Tian, Jing Zhang, Keke Li, Lele Wang, Jingtian Han, Zimei Wu
Gemcitabine (GEM) and paclitaxel (PTX) are effective combination anticancer agents against non-small-cell lung cancer (NSCLC). At the present time, a main challenge of combination treatment is the precision of control that will maximize the combined effects. Here, we report a novel method to load GEM (hydrophilic) and PTX (hydrophobic) into simplex tumor-targeted nanostructured lipid carriers (NLCs) for accurate control of the ratio of the two drugs. We covalently preconjugated the dual drugs through a hydrolyzable ester linker to form drug conjugates...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28155658/knockdown-of-pola2-increases-gemcitabine-resistance-in-lung-cancer-cells
#19
Vivien Koh, Hsueh Yin Kwan, Woei Loon Tan, Tzia Liang Mah, Wei Peng Yong
BACKGROUND: Gemcitabine is used as a standard drug treatment for non-small cell lung cancer (NSCLC), but treatment responses vary among patients. Our previous studies demonstrated that POLA2 + 1747 GG/GA single nucleotide polymorphism (SNP) improves differential survivability and mortality in NSCLC patients. Here, we determined the association between POLA2 and gemcitabine treatment in human lung cancer cells. RESULTS: Human PC9, H1299 and H1650 lung cancer cell lines were treated with 0...
December 22, 2016: BMC Genomics
https://www.readbyqxmd.com/read/28119812/inhalable-oridonin-loaded-poly-lactic-co-glycolic-acid-large-porous-microparticles-for-in-situ-treatment-of-primary-non-small-cell-lung-cancer
#20
Lifei Zhu, Miao Li, Xiaoyan Liu, Lina Du, Yiguang Jin
Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Traditional chemotherapy for this disease leads to serious side effects. Here we prepared an inhalable oridonin-loaded poly(lactic-co-glycolic)acid (PLGA) large porous microparticle (LPMP) for in situ treatment of NSCLC with the emulsion/solvent evaporation/freeze-drying method. The LPMPs were smooth spheres with many internal pores. Despite a geometric diameter of ~10 µm, the aerodynamic diameter of the spheres was only 2.72 µm, leading to highly efficient lung deposition...
January 2017: Acta Pharmaceutica Sinica. B
keyword
keyword
43169
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"